Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own

Taking stock of the drug industry, from the lab to the medicine chest

May 17, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sarah Gonzalez for STAT STAT+ | Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own With positive topline results of its treatment, aficamten, the company has come under pressure to sell itself to a large drugmaker. By Elaine Chen Animal studies lend support to an innovative HIV vaccine strategy — but there's still a long way to go Animal studies show broadly neutralizing antibodies, which could recognize and attack HIV strains, can be made by cultivating extremely rare B cells. By Annalisa Merelli and Jonathan Wosen STAT+ | Data integrity watchdogs call for stronger safeguards in scientific journals AI-generated images and manipulated data are infiltrating scientific journals and more needs to be done, watchdogs said Thursday. By Angus Chen Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser